Renal cell carcinoma (RCC) is one of the most common malignancies among our Veterans. The main goal of this project is to investigate the role of miRNAs in targeting c-Myc/HIF pathway and thus suppress kidney cancer progression and metastasis using both in vitro and in vivo models. The major barrier or clinical challenge is that despite the recent advances in the understanding of the biological basis of RCC, the management of the disease, especially in the advanced metastatic phase, remains a significant challenge. Molecular understanding of pathways associated with kidney cancer progression may lead to better diagnosis, prognosis and therapeutic strategies against kidney cancer. Based on the preliminary data and published literature, c-Myc/HIF pathway is involved in the progression and metastasis of kidney cancer. We have identified a set of miRNAs that can target c-Myc/HIF pathway and thus may play an important role in inhibition of kidney cancer progression and metastasis through targeting this pathway. The rationale is that the c-Myc/HIF pathway coordinates complex multifunctional events and has a wide range of downstream targets that regulate tumor-associated cell processes such as cell growth, cell cycle, survival, migration, epithelial-mesenchymal transition and angiogenesis in kidney cancer. The role of the miRNA network that regulates the c-Myc/HIF pathway is only beginning to be explored and such studies are lacking in kidney cancer. In this project we will investigate the role of a set of miRNAs in regulation of the c-Myc/HIF pathway that in turn inhibit kidney cancer progression and metastasis. To address this problem, we hypothesize that a set of miRNAs may directly target the c-Myc/HIF pathway and thereby inhibit kidney cancer progression and metastasis. To test this hypothesis, we have proposed a series of in vitro and in vivo experiments described under specific aims.
Specific Aim # 1. To investigate the mechanisms of miRNA-mediated inhibition of c-Myc/HIF pathway in suppression of kidney cancer progression and metastasis using both in vitro and in vivo models.
Specific Aim # 2: To investigate the molecular mechanisms of alteration of a set of miRNAs in kidney cancer.
Specific Aim # 3. To investigate whether expression profile of a set of miRNAs can predict clinical outcome of kidney cancer patients. Accomplishment of this project will be a significant step forward in understanding miRNA-mediated suppression of c-Myc/HIF pathway and designing novel miRNA-based therapeutic strategies for inhibition of progression and metastasis of kidney cancer among our Veterans.

Public Health Relevance

Renal cell carcinoma (RCC) is one of the most common malignancies among our Veterans. The major barrier or clinical challenge is that despite the recent advances in the understanding of the biological basis of RCC, the management of the disease, especially in the advanced metastatic phase, remains a significant challenge. The rationale is that the c-Myc/HIF pathway is important in kidney cancer progression and metastasis. To address this problem, we will investigate the role of a set of miRNAs that directly target the c-Myc/HIF pathway and thereby inhibit kidney cancer progression and metastasis. Accomplishment of this study will be a significant step forward in understanding miRNA-mediated regulation of the c-Myc/HIF pathway and designing novel miRNA-based therapeutic strategies for metastatic kidney cancer among our Veterans. We believe that the work proposed is highly relevant to Veterans health and the VA mission.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX001123-08
Application #
9814669
Study Section
Oncology A (ONCA)
Project Start
2011-10-01
Project End
2020-09-30
Budget Start
2019-10-01
Budget End
2020-09-30
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Veterans Affairs Medical Center San Francisco
Department
Type
DUNS #
078763885
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Kulkarni, Priyanka; Dasgupta, Pritha; Bhat, Nadeem S et al. (2018) Elevated miR-182-5p Associates with Renal Cancer Cell Mitotic Arrest through Diminished MALAT-1 Expression. Mol Cancer Res 16:1750-1760
Dasgupta, Pritha; Kulkarni, Priyanka; Majid, Shahana et al. (2018) MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma. Mol Cancer Ther 17:1061-1069
Fujii, Nakanori; Hirata, Hiroshi; Ueno, Koji et al. (2017) Extracellular miR-224 as a prognostic marker for clear cell renal cell carcinoma. Oncotarget 8:109877-109888
Yoshino, Hirofumi; Nohata, Nijiro; Miyamoto, Kazutaka et al. (2017) PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2?-Targeting Therapy for Renal Cell Carcinoma. Cancer Res 77:6321-6329
Bhat, Nadeem S; Colden, Melissa; Dar, Altaf A et al. (2017) MicroRNA-720 Regulates E-cadherin-?E-catenin Complex and Promotes Renal Cell Carcinoma. Mol Cancer Ther 16:2840-2848
Mitsui, Yozo; Shiina, Hiroaki; Kato, Taku et al. (2017) Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma. Mol Cancer Res 15:884-895
Hirata, Hiroshi; Hinoda, Yuji; Shahryari, Varahram et al. (2015) Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res 75:1322-31
Hirata, H; Hinoda, Y; Shahryari, V et al. (2014) Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer 110:1645-54
Hirata, H; Ueno, K; Nakajima, K et al. (2013) Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. Br J Cancer 108:2070-8
Hirata, Hiroshi; Hinoda, Yuji; Ueno, Koji et al. (2012) MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis 33:501-8